Free Trial

ANI Pharmaceuticals (ANIP) News Today

$58.53
-0.86 (-1.45%)
(As of 06/21/2024 ET)
ANI Pharmaceuticals logo with Medical background
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Passes Below 200 Day Moving Average of $61.19
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Passes Below 200 Day Moving Average of $61.19
ANI Pharmaceuticals logo with Medical background
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 250 Shares
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 250 shares of the stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $63.80, for a total transaction of $15,950.00. Following the transaction, the vice president now directly owns 59,231 shares of the company's stock, valued at $3,778,937.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
ANI Pharmaceuticals logo with Medical background
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Update
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the target of a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 339,100 shares, a growth of 65.9% from the May 15th total of 204,400 shares. Based on an average daily trading volume, of 153,400 shares, the days-to-cover ratio is currently 2.2 days.
ANI Pharmaceuticals logo with Medical background
Rubric Capital Management LP Purchases 277,989 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Rubric Capital Management LP grew its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 32.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,125,000 shares of the specialty pharmaceutical company's stoc
ANI Pharmaceuticals logo with Medical background
Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells 2,985 Shares of Stock
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Ori Gutwerg sold 2,985 shares of the stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $67.00, for a total value of $199,995.00. Following the completion of the transaction, the senior vice president now owns 77,227 shares in the company, valued at approximately $5,174,209. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
ANI Pharmaceuticals logo with Medical background
Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells 20,000 Shares of Stock
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $64.41, for a total value of $1,288,200.00. Following the completion of the transaction, the senior vice president now owns 213,226 shares in the company, valued at $13,733,886.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
ANI Pharmaceuticals logo with Medical background
Dimensional Fund Advisors LP Boosts Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Dimensional Fund Advisors LP lifted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 6.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 591,731 shares of the specialty pharmaceu
ANI Pharmaceuticals logo with Medical background
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Large Decrease in Short Interest
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 204,400 shares, a decline of 11.1% from the April 30th total of 229,900 shares. Based on an average daily trading volume, of 159,600 shares, the days-to-cover ratio is currently 1.3 days.
ANI Pharmaceuticals logo with Medical background
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Buy" from Analysts
Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have earned an average recommendation of "Buy" from the four brokerages that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation. The average 1-year price ob
ANI Pharmaceuticals logo with Medical background
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Trexquant Investment LP
Trexquant Investment LP decreased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 34.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,484 shares of the speci
Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Insider Sells 2,000 Shares of Stock
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) insider Christopher Mutz sold 2,000 shares of the stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $61.61, for a total value of $123,220.00. Following the completion of the sale, the insider now directly owns 83,277 shares in the company, valued at approximately $5,130,695.97. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Sells 12,855 Shares of Stock
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) COO Muthusamy Shanmugam sold 12,855 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $61.81, for a total transaction of $794,567.55. Following the transaction, the chief operating officer now owns 732,620 shares in the company, valued at $45,283,242.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Global Alpha Capital Management Ltd. Increases Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Global Alpha Capital Management Ltd. boosted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 10.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 582,428 shares of the specialty pharmaceutical company's stock after acquiring an addition
ANI Pharma Launches Kionex Suspension For Oral Or Rectal Use
Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Sells 16,669 Shares of Stock
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CEO Nikhil Lalwani sold 16,669 shares of the company's stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $66.10, for a total value of $1,101,820.90. Following the transaction, the chief executive officer now owns 377,505 shares of the company's stock, valued at $24,953,080.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Meredith Cook Sells 250 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 250 shares of the company's stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $67.69, for a total transaction of $16,922.50. Following the transaction, the vice president now owns 59,481 shares of the company's stock, valued at $4,026,268.89. The transaction was disclosed in a filing with the SEC, which is available through this link.
ANI Pharmaceuticals (NASDAQ:ANIP) PT Raised to $87.00
HC Wainwright boosted their price target on ANI Pharmaceuticals from $83.00 to $87.00 and gave the stock a "buy" rating in a research report on Monday.
Thompson Siegel & Walmsley LLC Sells 15,796 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Thompson Siegel & Walmsley LLC decreased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 6.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 212,911 shares of the s
ANI: Q1 Earnings Snapshot
ANI Pharmaceuticals, Inc. Q1 Profit Increases, Beats Estimates
ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY24 Earnings Guidance
ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY24 earnings guidance. The company provided EPS guidance of $4.26-4.67 for the period, compared to the consensus estimate of $4.48. The company also issued revenue guidance of $520-542 millionillion, compared to the consensus estimate of $535.14 millionillion.
Summit Global Investments Invests $773,000 in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Summit Global Investments bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,027 shares of the specialty pharmaceuti
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells $1,332,400.00 in Stock
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Chad Gassert sold 20,000 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $66.62, for a total value of $1,332,400.00. Following the completion of the sale, the senior vice president now directly owns 233,226 shares of the company's stock, valued at $15,537,516.12. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Get ANI Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

Bill Clinton Backing Biden Replacement??? (Ad)

Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.

Click here to see why it will be ______ _________.

ANIP Media Mentions By Week

ANIP Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ANIP
News Sentiment

0.67

0.71

Average
Medical
News Sentiment

ANIP News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ANIP Articles
This Week

2

4

ANIP Articles
Average Week

Get ANI Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ANIP) was last updated on 6/23/2024 by MarketBeat.com Staff

From Our Partners